In order to add next-generation therapeutics to its already broad immuno-oncology pipeline, Bristol-Myers Squibb has partnered with Five Prime Therapeutics to discover novel interacting proteins in two undisclosed immune checkpoint pathways using Five Prime’s target discovery platform and to discover and preclinically develop immunotherapeutics against these targets. Combinations of immunotherapeutics are expected to form the foundation of many future cancer therapy regimens, thus driving deal-making activity in the immuno-oncology field.